A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of H10N8 Antigen mRNA in Healthy Adult Subjects

Trial Profile

A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of H10N8 Antigen mRNA in Healthy Adult Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs MRNA 1440 (Primary)
  • Indications Influenza A virus infections
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Moderna Therapeutics
  • Most Recent Events

    • 20 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
    • 20 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
    • 27 Apr 2017 According to a Moderna Therapeutics media release, patient follow-up is ongoing and the company plans to publish full study findings upon study completion and data analysis in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top